Abstract:Background: Activation of adenosine monophosphate-activated kinase (AMPK) has been associated with the inhibition of inflammatory nociception and the attenuation of morphine antinociceptive tolerance. In this study, the authors investigated the impact of AMPK activation through resveratrol treatment on bone cancer pain.Methods: The nociception was assessed by measuring the incidence of foot withdrawal in response to mechanical indentation in rats (n = 8). Cytokine expression was measured using quantitative polymerase chain reaction (n = 8). Cell signalings were assayed by western blot (n = 4) and immunohistochemistry (n = 5). The microglial cell line BV-2, primary astrocytes, and neuron-like SH-SY5Y cells were cultured to investigate the in vitro effects.Results: Resveratrol and 5-amino-1--d-ribofuranosyl-imidazole-4-carboxamide, the AMPK activators, significantly attenuated bone cancer pain in rats with tumor cell implantation (TCI; threshold of mechanical withdrawal, resveratrol vs. vehicle: 10.1 0.56 vs. 4.1 +/- 0.37; 5-amino-1--d-ribofuranosyl-imidazole-4-carboxamide vs. vehicle: 8.2 +/- 0.17 vs. 4.1 +/- 0.37, mean +/- SEM); these effects were reversed by the AMPK inhibitor compound C (compound C vs. resveratrol: 6.2 +/- 1.35 vs. 10.1 +/- 0.56, mean +/- SEM). Resveratrol has an AMPK-dependent inhibitory effect on TCI-evoked astrocyte and microglial activation. The antinociceptive effects of resveratrol were partially mediated by the reduced phosphorylation of mitogen-activated protein kinases and decreased production of proinflammatory cytokines in an AMPK-dependent manner. Furthermore, resveratrol potently inhibited inflammatory factors-mediated protein kinase B/mammalian target of rapamycin signaling in neurons. Acute pain evoked by proinflammatory cytokines in the spinal cord was significantly attenuated by resveratrol.Conclusions: AMPK activation in the spinal glia by resveratrol may have utility in the treatment of TCI-induced neuroinflammation, and our results further implicate AMPK as a novel target for the attenuation of bone cancer pain.

AMPK activation attenuates cancer-induced bone pain by reducing mitochondrial dysfunction-mediated neuroinflammation

Activation of Adenosine Monophosphate–activated Protein Kinase Suppresses Neuroinflammation and Ameliorates Bone Cancer Pain

Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord

Glycogen synthase kinase‐3β inhibition decreases inflammation and relieves cancer induced bone pain via reducing Drp1‐mediated mitochondrial damage

AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome.

Activation of the Camp-Pka Signaling Pathway in Rat Dorsal Root Ganglion and Spinal Cord Contributes Toward Induction and Maintenance of Bone Cancer Pain.

AMPK activation attenuates inflammatory pain through inhibiting NF-κB activation and IL-1β expression

Extracellular Signal-Regulated Kinase Activation in Spinal Astrocytes and Microglia Contributes to Cancer-Induced Bone Pain in Rats

Pharmacological inhibition of the NLRP3 inﬂammasome as a potential target for cancer-induced bone pain

The inhibition of spinal synaptic plasticity mediated by activation of AMP-activated protein kinase signaling alleviates the acute pain induced by oxaliplatin

P2Y12 Receptor-Mediated Activation of Spinal Microglia and P38mapk Pathway Contribute to Cancer-Induced Bone Pain

Modulation of Rat Cancer-Induced Bone Pain is Independent of Spinal Microglia Activity

Inhibition of Glial Activation in Rostral Ventromedial Medulla Attenuates Mechanical Allodynia in a Rat Model of Cancer-Induced Bone Pain

LY294002 alleviates bone cancer pain by reducing mitochondrial dysfunction and the inflammatory response

Activation of C-Jun N-terminal Kinase in Spinal Cord Contributes to Breast Cancer Induced Bone Pain in Rats

PGC‐1α activation ameliorates cancer-induced bone pain via inhibiting apoptosis of GABAergic interneurons

Spinal Ifn-Gamma-Induced Protein-10 (Cxcl10) Mediates Metastatic Breast Cancer-Induced Bone Pain By Activation Of Microglia In Rat Models

Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3

Regulatory role of PI3K/Akt/WNK1 signal pathway in mouse model of bone cancer pain

The AMPK pathway triggers autophagy during CSF1-induced microglial activation and may be implicated in inducing neuropathic pain

Involvement of Adrenomedullin in Bone Cancer Pain in Rats